Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC

NCT03673735 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Company withdrew interest

Conditions

Squamous Cell Head and Neck Carcinoma

Interventions

DRUG: Durvalumab
RADIATION: radiotherapy
DRUG: Placebo
DRUG: Cisplatin

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC